

Papua New Guinea

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Papua New G	uinea							
2.	Vaccine gran	nt number:	13-PNG-08a-Y, 1315-PNG-12c-X, 16-PNG-12c-X, 17-PNG-12c-X, 18-PNG-12c-X, 1920-PNG-12c-X							
3.	Date of Decision Letter: 30/09/2019									
4.	Date of the Partnership Framework Agreement (PFA): 29/11/2013									
5.	Programme title: New Vaccine Support (NVS), Pneumococcal , Routine									
6.	Vaccine type:		Pneumococcal							
7.	Requested product presentation and formulation of vaccine:									
	PCV13, 1 dose(s) per vial LIQUID									
8. 9.	Programme Duration:1 2013-2020 Programme Product (indicative):2 (subject to the terms of the PEA if applicable)									
9.										
			2013-2019		2020		Total ²			
	Programme E	Budget (US\$)		9,232,797		800,500	10,033,2	297		
10.	Vaccine intro	oduction gran	nt							
	Approval									
	Year		Grant Number		Amount (US\$)					
		2013		G-08a-Y	Amoun	180,852				
						100,000				
		Dishuras	Net Disbursement							
	Disburse				180,852					
	22 July, 2013 180,852									
11.	Product switch grant: Not applicable									
12.	Indicative Annual Amounts: ³ (subject to the terms of the PFA, if applicable)									
	Type of s	upplies to be								
	purchased with Gavi funds Number of vaccine doses									
				2013-2019		2020	20	021		
						166,100				
	Annual Amounts (US\$)			9,232,797		800,500				
13.	Procuremen	ocurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.								
14.	Self-procure	ment:	Not applicable							
15.	Co-financing obligations: According to the co-financing policy, the Country falls within the group: Accelerated transition									

 $^{^{\}rm 1}$ This is the entire duration of the programme. $^{\rm 2}$ This is the total amount endorsed by Gavi for the entire duration of the programme. $^{\rm 3}$ This is the amount that Gavi has approved.



The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year		
Number of vaccine doses	850,600	
Number of AD syringes	843,000	
Number of re-constitution syringes	-	
Number of safety boxes	9,300	
Value of vaccine doses (US\$)	2,806,908	
Total co-financing payments (US\$) (including freight)	2,938,500	

16. Operational support for campaigns: Not applicable

17. Additional Reporting Requirements:

		Due dates
	or the annual procurement of vaccines, Country shall submit the ormation each year:	
•	Vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	
	ce with applicable Gavi processes, Country shall report on ic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019